1. Home
  2. FLNC vs AKRO Comparison

FLNC vs AKRO Comparison

Compare FLNC & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FLNC
  • AKRO
  • Stock Information
  • Founded
  • FLNC 2018
  • AKRO 2017
  • Country
  • FLNC United States
  • AKRO United States
  • Employees
  • FLNC N/A
  • AKRO N/A
  • Industry
  • FLNC Industrial Machinery/Components
  • AKRO Biotechnology: Pharmaceutical Preparations
  • Sector
  • FLNC Miscellaneous
  • AKRO Health Care
  • Exchange
  • FLNC Nasdaq
  • AKRO Nasdaq
  • Market Cap
  • FLNC 2.4B
  • AKRO 2.1B
  • IPO Year
  • FLNC 2021
  • AKRO 2019
  • Fundamental
  • Price
  • FLNC $22.01
  • AKRO $31.59
  • Analyst Decision
  • FLNC Buy
  • AKRO Strong Buy
  • Analyst Count
  • FLNC 17
  • AKRO 7
  • Target Price
  • FLNC $27.35
  • AKRO $43.20
  • AVG Volume (30 Days)
  • FLNC 1.3M
  • AKRO 441.5K
  • Earning Date
  • FLNC 11-26-2024
  • AKRO 11-11-2024
  • Dividend Yield
  • FLNC N/A
  • AKRO N/A
  • EPS Growth
  • FLNC N/A
  • AKRO N/A
  • EPS
  • FLNC N/A
  • AKRO N/A
  • Revenue
  • FLNC $2,143,395,000.00
  • AKRO N/A
  • Revenue This Year
  • FLNC $27.28
  • AKRO N/A
  • Revenue Next Year
  • FLNC $44.10
  • AKRO N/A
  • P/E Ratio
  • FLNC N/A
  • AKRO N/A
  • Revenue Growth
  • FLNC 7.87
  • AKRO N/A
  • 52 Week Low
  • FLNC $12.74
  • AKRO $11.36
  • 52 Week High
  • FLNC $27.80
  • AKRO $37.00
  • Technical
  • Relative Strength Index (RSI)
  • FLNC 53.21
  • AKRO 66.34
  • Support Level
  • FLNC $20.00
  • AKRO $29.34
  • Resistance Level
  • FLNC $21.65
  • AKRO $32.15
  • Average True Range (ATR)
  • FLNC 0.96
  • AKRO 1.26
  • MACD
  • FLNC -0.08
  • AKRO 0.10
  • Stochastic Oscillator
  • FLNC 65.79
  • AKRO 99.74

About FLNC Fluence Energy Inc.

Fluence Energy Inc is enabling the global clean energy transition with market-leading energy storage products and services, and digital applications for renewables and storage. Geographically, it derives a majority of its revenue from the Americas.

About AKRO Akero Therapeutics Inc.

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.

Share on Social Networks: